Find new investment opportunities based on Market Sentiment Indicator. Manage watchlist risk with leading indicator of volatility See what influential analysts and investors are saying about stocks in your watchlist
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
GILD
Gilead Sciences
$108.00
Chart
$98.16 (+10.02%)
$109.27 (-1.16%)
$109.27 (-1.16%)
$66.69 (+61.94%)
FIND US ON
Join over 10,000+ subscribers who value exclusive insights. Stay ahead in the stock market! Enter your email for daily alerts
Stay ahead of the market
Market trends
Investment tips
Market analysis service
Future potential
Informed investment decisions
Investment analysis
IInvestment strategies
In-depth stock analysis
Performance analysis
Stock market insights
Financial trends analysis
Most Trending
0.00%
+0.49%
+0.94%
-2.97%
-1.83%
GILD
Gilead Sciences
Current Price
$108.00
Login to view Gilead Sciences (GILD) recommendation from the last 90 days from financial news and social media.
Chart
$98.16 (+10.02%)
$109.27 (-1.16%)
$109.27 (-1.16%)
$66.69 (+61.94%)
GILD Latest Analysis
Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug. Gilead Sciences won Food and Drug Administration approval Wednesday for a highly effective drug to prevent HIV infection.The post Gilead Sciences Wins Approval For Highly Effective HIV Prevention Drug appeared first on Investor'.s Business Daily.
Wed Jun 18, 2025
FDA approves Gileads twice-yearly HIV prevention injection offering a powerful and convenient new option. The launch of the injection faces potential threats including the Trump administrations proposed cuts to federal funding for HIV prevention efforts.
Wed Jun 18, 2025
Gilead wins FDA approval for twice-yearly HIV PrEP therapy.
Wed Jun 18, 2025
Gileads HIV Prevention Drug Could Be Manufactured At Shocking Low Cost: Report. ) is facing mounting pressure to price its drug lenacapavir affordably as it prepares for United States regulatory approval on June 19.In December 2022 the FDA Lenacapavir in combination with other antiretrovirals to treat HIV-1 infection in heavily treatment-experienced adults with multi-drug resistant HIV-1 infection.Researchers and global health leaders are urging the company to ensure widespread access especial
Tue Jun 17, 2025
Ex-Dividend Reminder: Gilead Sciences CONMED and Thermo Fisher Scientific . Looking at the universe of stocks we cover at Dividend Channel on 6/13/25 Gilead Sciences Inc (Symbol: GILD) CONMED Corp (Symbol: CNMD) and Thermo Fisher Scientific Inc (Symbol: TMO) will all trade ex-dividend for their respective upcoming dividends. Gilead Sciences Inc will
Wed Jun 11, 2025
Gilead Sciences Inc. (GILD) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript.
Tue Jun 10, 2025
McRae Industries Inc.Dividend Declared. MOUNT GILEAD N.C. June 5 2025 /PRNewswire/ -- McRae Industries Inc. (Pink Sheets: MCRAA and MCRAB) declared a dividend of $.14 per share on the Companys Class A and Class B Common Stock payable on July 2 2025 to shareholders of record on June 18 2025. View original...
Thu Jun 5, 2025
Gileads HIV Pipeline Gains Traction With Upcoming FDA Decision For HIV-1 Drug. In February the United States Food and Drug Administration (FDA) accepted ) New Drug Application (NDA) submissions for lenacapavir — the company’.s twice-yearly injectable HIV-1 capsid inhibitor — for the prevention of HIV as pre-..In June 2024 Gilead Sciences shared topline results from an interim analysis of its Phase 3 PURPOSE 1 trial indicating its twice-yearly lenacapavirdemonstrated 100% efficacy for the in
Thu Jun 5, 2025
Healthy Returns: AstraZeneca Pfizer Gilead and other drugmakers release promising cancer drug data at ASCO. Drugmakers unveil cancer drug data at the ASCO annual meeting while Amazon Pharmacy announces new features for caregivers Medicare patients.
Tue Jun 3, 2025
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today. Gilead Sciences (NASDAQ:) has outperformed the market over the past 20 years by 3.99% on an annualized basis producing an average annual return of 12.25%. Currently Gilead Sciences has a market capitalization of $136.78 billion.
Mon Jun 2, 2025
FIND US ON
Unlock the knowledge that 10,000+ subscribers already cherish. Join for exclusive insights and stay ahead in the stock game! Enter your email to receive daily alerts
In-depth stock analysis
Informed investment decisions
Stock market insights
Stock trading tips
GILD Stock trends
GILD Stock performance
GILD Stock analysis
GILD investment strategies
Disclaimer:
Past performance, whether from actual results or historical strategy tests, does not guarantee future success. The displayed outcomes are based on strategies not previously available to investors and do not depict the returns achieved by any specific investor.
The Readiness Indicators, Sentiment Indicators, and overall score are derived from a model retrospectively applied using historical data. This model relies on assumptions inherent to it, which may or may not be verifiable and carry potential risks, including losses.
Engaging in active trading may not be suitable for individuals with limited resources, minimal investment or trading experience, or a low-risk tolerance. Proceed with caution as your capital is exposed to risks.
Please note that no offer or solicitation to buy or sell securities, securities derivatives of future products of any kind, or any type of trading or invesment advise, recommendation or strategy, is made, given or endorsed by StocksRunner including any of their affiliates ("TS").
This information is provided for illustrative purposes only. You should not rely on any advice and/or information contained in this website and before making any investment decision. we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice.
Hover over the category for more information
